Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor

Leopoldo Laricchia Robbio, Patrizia Uboldi, Santica Marcovina, Roberto P. Revoltella, Alberico L. Catapano

Research output: Contribution to journalArticle

Abstract

Using a surface plasmon resonance (SPR)-based biosensor (BIA-technology), we have studied the interaction of ten different murine monoclonal antibodies (mAbs, all IgG1), raised against the main protein constituent of human low density lipoprotein (LDL), i.e. the apolipoprotein B-100 (apoB-100). These mAbs identify distinct domains on apoB-100, relevant to LDL-receptor interaction: epitopes in the amino-terminal region (mAbs L7, L9, L10 and L11: aa 1-1297) and in the middle region (mAb 6B: aa 1480-1693; mAbs 2A, 3B: aa 2152-2377; mAbs 9A, L2 and L4: aa 2657-3248) of native apoB-100. A multisite binding analysis was performed to further characterize the epitopes recognized by all these mAbs. A rabbit anti-mouse IgG1-Fc antibody (RAM.Fc) was first coupled to the gold surface in order to capture one anti-human apoB-100 mAb. ApoB-100 protein was subsequently injected and allowed to react with this immobilized, oriented antibody. Multisite binding assays were then performed, by sequentially flowing other mAbs, in different orders, over the sensing surface. The capacity of each mAb to interact with the entrapped apoB-100 in a multimolecular complex was monitored in real time by SPR. The results achieved were comparable to those obtained by western immunoblotting using the same reagents. However, SPR ensures a more detailed epitope identification, demonstrating that BIA-technology can be successfully used for mapping distinct epitopes on apoB-100 protein in solution dispensing with labels and secondary tracers; moreover, compared with conventional immunoassays, it is significantly time saving (CNR-P.F. MADESS 2).

Original languageEnglish
Pages (from-to)963-969
Number of pages7
JournalBiosensors and Bioelectronics
Volume16
Issue number9-12
DOIs
Publication statusPublished - 2001

Fingerprint

Apolipoprotein B-100
Epitope Mapping
Epitopes
Surface Plasmon Resonance
Surface plasmon resonance
Biosensing Techniques
Biosensors
Lipoproteins
Proteins
Antibodies
Immunoglobulin G
Monoclonal antibodies
Immobilized Antibodies
Technology
LDL Receptors
Apolipoproteins
Labels
LDL Lipoproteins
Assays
Immunoassay

Keywords

  • BIA-technology
  • Epitope mapping
  • Immunosensors
  • Low density lipoprotein

ASJC Scopus subject areas

  • Biotechnology
  • Analytical Chemistry
  • Electrochemistry

Cite this

Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. / Robbio, Leopoldo Laricchia; Uboldi, Patrizia; Marcovina, Santica; Revoltella, Roberto P.; Catapano, Alberico L.

In: Biosensors and Bioelectronics, Vol. 16, No. 9-12, 2001, p. 963-969.

Research output: Contribution to journalArticle

Robbio, Leopoldo Laricchia ; Uboldi, Patrizia ; Marcovina, Santica ; Revoltella, Roberto P. ; Catapano, Alberico L. / Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor. In: Biosensors and Bioelectronics. 2001 ; Vol. 16, No. 9-12. pp. 963-969.
@article{9c56547ac1ea4bd0856ebbec8e428a11,
title = "Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor",
abstract = "Using a surface plasmon resonance (SPR)-based biosensor (BIA-technology), we have studied the interaction of ten different murine monoclonal antibodies (mAbs, all IgG1), raised against the main protein constituent of human low density lipoprotein (LDL), i.e. the apolipoprotein B-100 (apoB-100). These mAbs identify distinct domains on apoB-100, relevant to LDL-receptor interaction: epitopes in the amino-terminal region (mAbs L7, L9, L10 and L11: aa 1-1297) and in the middle region (mAb 6B: aa 1480-1693; mAbs 2A, 3B: aa 2152-2377; mAbs 9A, L2 and L4: aa 2657-3248) of native apoB-100. A multisite binding analysis was performed to further characterize the epitopes recognized by all these mAbs. A rabbit anti-mouse IgG1-Fc antibody (RAM.Fc) was first coupled to the gold surface in order to capture one anti-human apoB-100 mAb. ApoB-100 protein was subsequently injected and allowed to react with this immobilized, oriented antibody. Multisite binding assays were then performed, by sequentially flowing other mAbs, in different orders, over the sensing surface. The capacity of each mAb to interact with the entrapped apoB-100 in a multimolecular complex was monitored in real time by SPR. The results achieved were comparable to those obtained by western immunoblotting using the same reagents. However, SPR ensures a more detailed epitope identification, demonstrating that BIA-technology can be successfully used for mapping distinct epitopes on apoB-100 protein in solution dispensing with labels and secondary tracers; moreover, compared with conventional immunoassays, it is significantly time saving (CNR-P.F. MADESS 2).",
keywords = "BIA-technology, Epitope mapping, Immunosensors, Low density lipoprotein",
author = "Robbio, {Leopoldo Laricchia} and Patrizia Uboldi and Santica Marcovina and Revoltella, {Roberto P.} and Catapano, {Alberico L.}",
year = "2001",
doi = "10.1016/S0956-5663(01)00244-5",
language = "English",
volume = "16",
pages = "963--969",
journal = "Biosensors and Bioelectronics",
issn = "0956-5663",
publisher = "Elsevier Ltd",
number = "9-12",

}

TY - JOUR

T1 - Epitope mapping analysis of apolipoprotein B-100 using a surface plasmon resonance-based biosensor

AU - Robbio, Leopoldo Laricchia

AU - Uboldi, Patrizia

AU - Marcovina, Santica

AU - Revoltella, Roberto P.

AU - Catapano, Alberico L.

PY - 2001

Y1 - 2001

N2 - Using a surface plasmon resonance (SPR)-based biosensor (BIA-technology), we have studied the interaction of ten different murine monoclonal antibodies (mAbs, all IgG1), raised against the main protein constituent of human low density lipoprotein (LDL), i.e. the apolipoprotein B-100 (apoB-100). These mAbs identify distinct domains on apoB-100, relevant to LDL-receptor interaction: epitopes in the amino-terminal region (mAbs L7, L9, L10 and L11: aa 1-1297) and in the middle region (mAb 6B: aa 1480-1693; mAbs 2A, 3B: aa 2152-2377; mAbs 9A, L2 and L4: aa 2657-3248) of native apoB-100. A multisite binding analysis was performed to further characterize the epitopes recognized by all these mAbs. A rabbit anti-mouse IgG1-Fc antibody (RAM.Fc) was first coupled to the gold surface in order to capture one anti-human apoB-100 mAb. ApoB-100 protein was subsequently injected and allowed to react with this immobilized, oriented antibody. Multisite binding assays were then performed, by sequentially flowing other mAbs, in different orders, over the sensing surface. The capacity of each mAb to interact with the entrapped apoB-100 in a multimolecular complex was monitored in real time by SPR. The results achieved were comparable to those obtained by western immunoblotting using the same reagents. However, SPR ensures a more detailed epitope identification, demonstrating that BIA-technology can be successfully used for mapping distinct epitopes on apoB-100 protein in solution dispensing with labels and secondary tracers; moreover, compared with conventional immunoassays, it is significantly time saving (CNR-P.F. MADESS 2).

AB - Using a surface plasmon resonance (SPR)-based biosensor (BIA-technology), we have studied the interaction of ten different murine monoclonal antibodies (mAbs, all IgG1), raised against the main protein constituent of human low density lipoprotein (LDL), i.e. the apolipoprotein B-100 (apoB-100). These mAbs identify distinct domains on apoB-100, relevant to LDL-receptor interaction: epitopes in the amino-terminal region (mAbs L7, L9, L10 and L11: aa 1-1297) and in the middle region (mAb 6B: aa 1480-1693; mAbs 2A, 3B: aa 2152-2377; mAbs 9A, L2 and L4: aa 2657-3248) of native apoB-100. A multisite binding analysis was performed to further characterize the epitopes recognized by all these mAbs. A rabbit anti-mouse IgG1-Fc antibody (RAM.Fc) was first coupled to the gold surface in order to capture one anti-human apoB-100 mAb. ApoB-100 protein was subsequently injected and allowed to react with this immobilized, oriented antibody. Multisite binding assays were then performed, by sequentially flowing other mAbs, in different orders, over the sensing surface. The capacity of each mAb to interact with the entrapped apoB-100 in a multimolecular complex was monitored in real time by SPR. The results achieved were comparable to those obtained by western immunoblotting using the same reagents. However, SPR ensures a more detailed epitope identification, demonstrating that BIA-technology can be successfully used for mapping distinct epitopes on apoB-100 protein in solution dispensing with labels and secondary tracers; moreover, compared with conventional immunoassays, it is significantly time saving (CNR-P.F. MADESS 2).

KW - BIA-technology

KW - Epitope mapping

KW - Immunosensors

KW - Low density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=0034776152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034776152&partnerID=8YFLogxK

U2 - 10.1016/S0956-5663(01)00244-5

DO - 10.1016/S0956-5663(01)00244-5

M3 - Article

C2 - 11679276

AN - SCOPUS:0034776152

VL - 16

SP - 963

EP - 969

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

SN - 0956-5663

IS - 9-12

ER -